Real-world characteristics and disease burden of patients with asthma prior to treatment initiation with mepolizumab or omalizumab: a retrospective cohort database study

PURPOSE: Patients with severe asthma are eligible for asthma-specific biologics as add-on therapies, such as mepolizumab and omalizumab, when optimized controller therapies are unable to control their symptoms. However, few real-world data are available to describe the characteristics and associated...

Descripción completa

Detalles Bibliográficos
Autores principales: Llanos, Jean-Pierre, Bell, Christopher F, Packnett, Elizabeth, Thiel, Ellen, Irwin, Debra E, Hahn, Beth, Ortega, Hector
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354698/
https://www.ncbi.nlm.nih.gov/pubmed/30774390
http://dx.doi.org/10.2147/JAA.S189676

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354698/
https://www.ncbi.nlm.nih.gov/pubmed/30774390
http://dx.doi.org/10.2147/JAA.S189676

Ejemplares similares